Bai Ling
Zhengyu Zhang2†
Ze Xiang
Yiqi Cai
Xinyue Zhang
Jian Wu- 1Department of Pharmacy, The Yancheng Clinical College of Xuzhou Medical University, The First people’s Hospital of Yancheng, Yancheng, China
- 2Nanjing Medical University School of Medicine, Nanjing, China
- 3Zhejiang University School of Medicine, Hangzhou, China
- 4Stomatology Hospital, School of stomatology, Zhejiang University School of Medicine, Zhejiang Provincial Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Research of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, China
- 5Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China
Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people’s life and health. Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model. By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets. The applications of proteomics have promoted the research on lung cancer. To figure out potential applications of proteomics associated with lung cancer, we summarized the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer in this review, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer.
Introduction
Although the incidence and mortality of lung cancer have decreased significantly in the past decade, it is still one of the leading causes of death, which greatly impairs people’s life and health (1). Every year, there is about 2.2 million new cases and 1.79 million deaths according to conservative estimation (2, 3). Lung cancer can be divided into two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), among which NSCLC is the major one (4). As one of the most frequent diagnosed cancers with heterogeneity, there has been always great burden of lung cancer diagnosis. Diagnosis of NSCLC often depends on clinical symptoms like cough, hemoptysis and chest pain, paraneoplastic syndromes, laboratory abnormalities and histologic confirmation, with staging by invasive methods including mediastinoscopy and mediastinal lymph node biopsy, or imaging technology (5). For SCLC, pathological diagnosis with immunohistochemistry and biopsy, and staging with Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and positron emission tomography (PET) are common screening approaches (6). But these methods are sometimes not that accurate, and have limitation in early diagnosis (5).
With the development of proteomics, hundreds of biomarkers have been found. As protein markers can reflect body status better than other kinds of biomarkers such as DNA (7), the explored biomarkers have greatly enhanced the accuracy of diagnosis in several certain diseases (8–10), and reduce some unnecessary invasive biopsies (11). Samples for clinical proteomics can be obtained from biopsy tissues and body fluid especially plasma, saliva, lavage fluid and effusion (5). Besides, proteomics can be integrated with other approaches for better patient stratifications and individual management based on more rational classification and earlier detection (12). However, increasing sensitivity and specificity still need to be improved (13, 14). The treatment of lung cancer consists of traditional radiotherapy, chemotherapy and surgery. Meanwhile, novel therapies including immunotherapy have also been developed. The advances and clinical applications of these new treatments have reinforced the need for accurate sub-classification of lung cancer (15). Furthermore, metastasis, recurrence and resistance are challenges for us.
Proteomics is an emerging technology that involves the application of techniques for identifying and quantifying the overall proteins in cells, tissues and organisms, and can be combined with genomics, transcriptomics to form a multi-omics research model (16). Proteomics focuses on the product of genes, also means the active substance in the cell, so it is dynamic and complex, and is also a good complement to genomics to show functions and interactions of proteins (17). By comparing the content of proteins between normal and tumor tissues, proteomics can be applied to different clinical aspects like diagnosis, treatment, and prognosis, especially the exploration of disease biomarkers and therapeutic targets (18). And the applications of proteomics have promoted the research on lung cancer.
To figure out potential applications of proteomics associated with lung cancer, this review summarizes the role of proteomics in studies about tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer, which will provide guidance for more rational application of proteomics and potential therapeutic strategies of lung cancer (Figure 1).
Figure 1 The application of proteomics in lung cancer.
Proteomic technologies
Traditional proteomics employs methods such as protein microarrays and electrophoresis, and the development of mass spectrometry expands the range of application of proteomics.
Electrophoresis includes SDS-PAGE (SDS, sodium dodecyl sulfate; PAGE, polyacrylamide gel electrophoresis), two-dimensional gel electrophoresis (2DE) and two-dimensional fluorescence difference gel electrophoresis (2D-DIGE), which have been widely used despite some obvious disadvantages like low throughput and obscuration of low abundance proteins (19).
Mass spectrometry has promoted the development of proteomics, especially quantitative proteomics. Technically, mass spectrometers are mainly composed of the ionization source, the mass analyzer, and the detector. In 1998, Tanaka, K. et al. first analyzed large molecules like proteins using matrix-assisted laser desorption ionization (MALDI) and a time-of-flight (TOF) mass spectrometer, which was named MALDI-TOF-MS technology later (20). While surface-enhanced laser desorption ionization with time-of-flight mass spectrometry (SELDI-TOF-MS) has become popular in the examination of protein expression differences in clinical settings because of its ease of use and good throughput ability (21). MALDI and SELDI are two most common platforms for mass spectrometry technology. However, because of the limitation of 2DE, MALDI and SELDI in proteome coverage, sensitivity and resolution, they have been gradually superseded by liquid-chromatography/mass spectrometry (LC/MS), which can assist other strategies for quantification (22).
Most of the time, quantitative proteomics can be divided into two main categories, labeled and label-free approaches. Labeled approaches include in vivo labeling and in vitro labeling. Stable isotope labeling by amino acids in cell culture (SILAC) is a simple, inexpensive, and accurate in vivo labeling approach, which can be applied in any cell culture system (23). For in vitro labeling, isobaric tag for relative and absolute quantitation (iTRAQ) shows greater capability to identify high abundance proteins (24), and tandem mass tags (TMT) allow identification of peptides from different samples with better ease and accuracy (25). Data acquiring methods used for quantification are mainly data-independent acquisition (DIA) and data-dependent acquisition (DDA). DIA usually employs spectral library searches, while DDA workflows are mostly based on sequence database searches (26). To summarize, more and more mature proteomic technologies allow better application of proteomics in researches related to lung cancer.
Role in the tumorigenesis and progression of lung cancer
The application of proteomics methods has substantially improved our knowledge about the genesis and progression of lung cancer. Some pathways or essential molecules associated with lung cancer were gradually identified through proteomics (Table 1). A study operated the foundational and differential proteomics revealed that βIII-tubulin, an isotype of β-tubulin expressed in neural tissues, which was believed to correlate with chemoresistance and poor survival, might be regulated by the PTEN/AKT axis to influence tumor proliferation and metastasis, and mspin, a tumor suppressor related to adherence was observed to increase significantly in TUBB3 knock-down NSCLC cells, accompanied by changes in cell morphology (27). Chen et al. found that USP9X could facilitate the genesis of NSCLC through the dual specificity protein kinase TTK, also known as MPS1 (28), a key regulator of the pindle assembly checkpoint which maintains genomic integrity (33). Besides, after analyzing 108 primary tumor tissues and 99 paired normal lung tissues from patients, Satpathy et al. described a proteogenomic landscape of LSCC, and identified NSD3, part of NSD family which plays a key role in chromatin regulation, as an alternative driver in LSCC with FGFR1 amplification (34). In addition, the early molecular events of lung cancer also deserve attention. In a study, proteomics was used to examine tracheal epithelial cells in bronchial brushing specimens of 15 people at different risk of lung cancer obtained from main stem bronchus when performing bronchoscopy. The total of 237 up-regulated proteins and 75 down-regulated proteins were identified, and subsequent Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis proved that the key enzymes in the glycolysis pathway, the tricarboxylic acid cycle, the pentose phosphate pathway, and the galactose and glycogen metabolism were all overexpressed, indicating that early events of metabolic reprogramming may occur in the cytologically normal bronchial epithelium of individuals at high risk of lung cancer. From the low-risk to high-risk group, the expression of proteins has a notable increase trend, including GLB1, PYGB, PGM1 and so on. These very early molecular events in lung cancer can help us to understand the occurrence of lung cancer further and provide new ideas for developing chemoprevention strategies (29).
Table 1 Role in the tumorigenesis and progression of lung cancer.
The metastasis of lung cancer is another important clinical issue. To explore the relevant mechanism of lung cancer metastasis, Chang et al. compared two groups of lung adenocarcinoma (LUAD) cell lines, low-metastatic CL1-0 and high-metastatic CL1-5 through proteomics, and they identified 68 proteins with different expressions in these two groups. The overexpression of A1AT in CL1-0 might significantly increase its invasiveness, while the expression of A1AT in CL1-5 was down-regulated, thereby reducing its invasiveness. This suggested that A1AT, a hydrolytic enzyme, may be closely related to the invasion and metastasis of LUAD cells (30). After a proteomics study by label-free quantitative analysis and N-terminal analysis on two groups of human NSCLC cell lines with different metastasis potentials, NCI-H1703 (primary cell, stage I) and NCI-H1755 (metastatic cell, stage IV), 11 quantitatively expressed proteins and 8 N-terminal peptides were identified with differential expression, and were enriched mostly in the adhesion-related pathways, which can determine the possible biomarkers for NSCLC metastasis (31). Besides, some systems were built to evaluate metastasis potentials, such as the MigExpress system, which was proposed to be used to assess NSCLC-associated migration factors and provide more comprehensive transcriptome and proteomic data related to NSCLC metastasis (32).
Role in the diagnosis of lung cancer
Proteomics can be used to discover new lung cancer biomarkers that can be applied to the diagnosis (Table 2). The related techniques have also been developed. Sun et al. used serum functional enzymes enriched in the glycolytic pathway in lung cancer patients to verify the Protein Elution Plate PEP technology combined with mass spectrometry, which can systematically monitor serum functional enzymes and may become a substitute method for biomarker sequence annotation (35).
Table 2 Role in the diagnosis of lung cancer.
In recent years, exosomes have received more and more attention in the exploration of tumor biomarkers (47). Sun et al. used label-free quantification to compare protein profiling in serum and saliva exosomes in healthy people and patients with lung cancer, and they found that 11 proteins with significant differences in both body fluids seem to serve as biomarkers for lung cancer diagnosis. These results also supported the hypothesis that circulating exosomes contain disease-associated proteins and can be detected in body fluids (36). Comparing the metastatic and non-metastatic NSCLC exosomes, Wang et al. found significant differences in the expression of lipopolysaccharide-binding proteins, and these proteins may be a driver of NSCLC metastasis, which can be used as potential biomarkers of NSCLC metastasis and therapeutic targets (37).
Some identified proteins can be used for better diagnosis and differentiation of lung cancer. AMBP, α2 macroglobulin and A1AT were shown to be endopeptidase inhibitor, which can promote the development of lung cancer. Boccellino et al. analyzed these three proteins quantitatively in the serum samples from 20 NSCLC patients and 10 health controls through multiple reaction monitor. AMBP can be lysed in vivo into two chains: α-1-microglobulin and inter-α-trypsin inhibitor light chain (also named bikunin). In advanced cancer, bikunin levels were elevated, A1AT levels were reduced, and the levels of α2 macroglobulin appeared to be independent of cancer stage, suggesting that these three proteins may be used to grade NSCLC in an early stage (38). Based on the proteomics methods, autoantibodies against α-enolase were considered potential biomarkers of NSCLC, and the combined detection of autoantibodies against α-enolase, carcinoembryonic antigen and cytokeratin 19 fragment could significantly improve the sensitivity of NSCLC diagnosis (39). Bouamrani et al. used surface-enhanced laser desorption ionization-time-of-flight mass spectrometry technology to perform in situ proteomic profiling in mouse and human lung cancer tissue samples, and they proved that this kind of direct tissue proteomic could distinguish glioblastomas from oligodendrogliomas effectively, suggesting the possible application of direct tissue proteomic analysis in lung cancer diagnosis (48). Patz et al. attempted to use the expression data of proteins in serum samples of 100 lung cancer patients as a training set, and they finally selected a group of proteins, including CEA, RBP, SCC, and A1AT. The combination of these four proteins showed desirable accuracy for the detection and diagnosis of lung cancer (40). The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden also proposed to use the proteomics sequencing platform to distinguish neuro-endocrine lung cancer phenotype patients from SCLC and large cell lung cancer patients better, which also provided the targeted early treatment strategies (49).
In recent days, screening and early detection of lung cancer has gained great attention to improve the survival and prognosis of patients, and proteomics made some contributions and provided potential early-stage diagnostic biomarkers. Exhaled breath condensate of 192 individuals including 48 different types of lung cancer patients was analyzed by proteomics, and indicated that cytokeratins might be potential biomarkers for early detection of lung cancer (50). Besides, Jiang et al. developed an effective platform based on the proteomic analysis of salivary samples collected from 89 early lung cancer patients, 11 advanced lung cancer patients and 50 healthy volunteers. The sensitivity and specificity were high enough to distinguish early cacer patients from healthy people (51). Pan et al. also constructed a panel of p53, HRas, and ETHE1 using a 2-phase strategy for early detection of lung cancer (52). Currently, NSCLC still lacks early detection markers, and always advances when diagnosed, which makes NSCLC a malignant disease with poor survival and prognosis. However, proteomics might help change this situation. Using agrocybe aegerita lectin 2 that has high affinity to GlcNAc (AALNL/AAL2) to enrich serum glycopeptides, PON1 was identified to differ between Stage I NSCLC and healthy controls in serum samples from 120 enrolled participants including 58 healthy, 25 benign, and 37 NSCLC subjects (53). Among subtypes of NSCLC, early diagnosis of LSCC has been focused on in recent days. The cell membrane proteins taken from tumor tissues and normal bronchial epithelial tissues in 10 patients with non-metastatic LSCC were examined by matrix-assisted laser desorption ionization-time of flight mass spectrometry, and 12 proteins were up-regulated while 7 downregulated in tumor tissues. Among the total of 19 candidate markers, CTSD and HSP60 were further verified by the western blotting, which may serve as new markers for early diagnosis of LSCC (41). Additionally, Kim et al. used chromatography-tandem mass spectrometry to examine apical surface fluid of squamous metaplastic normal human tracheobronchial epithelial (NHTBE) and mucous NHTBE cells, and eventually they verified 6 differentially expressed proteins, especially SCCA1 (a cysteine proteases inhibitor) and SCCA2 (both serine and cysteine proteases inhibitor), which were expressed only in squamous metaplastic NHTBE cells. These candidate proteins might be used for early diagnosis of LSCC (42). Furthermore, four fucosylated proteins, including APCS, C9, SERPINA4, and PON1, were identified through multiple reaction monitoring-mass spectrometry by Ahn et al., which were proved to be of high value for SCLC diagnosis. In the plasma of SCLC patients, the level of PON1 was significantly reduced, while the fucosylation level of PON1 was significantly increased, suggesting that PON1 and its fucosylation level can be used as a diagnostic marker of SCLC (43). There also exist researches studying early diagnostic protein markers for LUAD, by analyzing lung tissue samples from different stages, a group of six candidate proteins including ERO1L, PABPC4, RCC1, RPS25, NARS, and TARS shown potential for early detection of LUAD (46).
For LUAD, more detection markers have been found, and Zhou et al. identified differentially expressed proteins in LUAD tissues and corresponding normal bronchial epithelial tissues from 7 patients. The mass spectrometric analysis found that 13 proteins were up-regulated and 9 proteins were down-regulated, of which two possible biomarkers, TyrRS and MACF-1, were identified by immunohistochemistry (44). The specific clinical application needs to be further explored. Meanwhile, QSOX1 was another biomarker validated by mass spectrometry to be significantly up-regulated in tumor tissues than in nearby normal tissues in lung cancer patients, and further studies found that QSOX1 can promote the metastasis potentials of lung cancer cells (7). Guergova-Kuras et al. used monoclonal antibody proteomic to analyze the plasma proteomes of 4 NSCLC clinical cohorts, and 13 lung cancer-related monoclonal antibodies were identified, and a total of five homologous proteins were selected. In two independent clinical data sets, a panel of these 5 biomarkers showed high sensitivity and specificity in diagnosing stage I NSCLC, and the combination of the panel of 5 biomarkers and a known cancer marker CYFRA could better improve the efficacy in diagnosis (45).
Besides, there exist specific differences based on sex in both clinical and molecular patterns, although these are always neglected. In NSCLC, better survival has been observed in women (54, 55), which might be related to the sex-biased differences especially those in expression of some functional proteins. Sex-based biomarkers can enhance the accuracy of diagnosis, Izbicka et al. explored plasma biomarkers in NSCLC patients with the help of multiplex immunoassays and mass spectrometry, and found that in male, sFas, MMP-9, and PAI-1 had higher expression, while in female, sCD40 had higher expression compared to that of healthy volunteers (56). Attention has also been focused on different immune state between male and female (57). It has been known that women usually have a stronger immune response than men, which can influence the tumorigenesis, diagnosis, treatment and prognosis. Ramsey et al. identified the level of 171 serum proteins in 1,676 participants and variations exist in the concentration of 56% of biomarkers between female and male, which was believed to contribute to deeper research (58). As relevant information are still limited, more researches are needed to explore sex-specific biomarkers with proteomics technology.
Role in the prognosis of lung cancer
Proteomics can have an important role in predicting the prognosis of patients with lung cancer, primarily by identifying expression of certain proteins. Dingemans et al. applied MALDI to successfully predict the survival outcomes based on pre-treatment serum samples in patients with phase IIIb or IV NSCLC accompanied with KRAS mutation (59). Additionally, HSP 90β was identified as a potential prognostic blood biomarker for LUAD based on mass spectrometry and was validated in an independent cohort of 705 LUAD patients and 282 healthy controls (60).
Proteomics can also be used to predict the possible metastasis of lung cancer. Liu et al. applied proteomics to non-metastatic 393P and metastatic 344SQ NSCLC cell lines to analyze protein expression differences in extracellular vesicles (EVs), and they demonstrated that Tspan8 was selectively highly expressed in 344SQ NSCLC cell lines. It was also confirmed that the abnormally high expression of Tspan8 can promote the metastasis potentials of NSCLC cells. Therefore, Tspan8 may be an ideal marker for predicting distal metastasis in patients with NSCLC (61). Moreover, the mitochondrial proteomic analysis of the high-metastatic large cell lung cancer cell line L-9981 and the low-metastatic NL-9980 was conducted. A total of 217 differentially expressed proteins were detected, of which 64 proteins with the most significant changes were further enriched and analyzed, indicating that these proteins were mostly related to redox reaction. This also suggested that metastasis of large cell lung cancer can be predicted by establishing a specific dataset of mitochondrial proteins (62).
Role in the treatment of lung cancer
Proteomics plays a very important role in the treatment of lung cancer. Based on the existing drugs, proteomics can help develop new targets, thereby promoting the advancement of lung cancer treatment strategies.
When it comes to the treatment of SCLC, proteomics is often used for identification and selection of possible targets. As a clinical common-used drug, bortezomib (BTZ) was found to induce the expression of an anti-apoptotic protein MCL-1 in 6 common human SCLC cell lines using a comprehensive proteomics analysis, thereby limiting its clinical efficacy. Otoclax (OBX) could cause obvious growth inhibition and apoptosis of SCLC when it was used with the combination of BTZ (63). The efficacy of this combination therapy needs more clinical trials for further assessment. Also, proteomics help identify potential targets for some clinical drugs. As a PARP inhibitor, the potent anti-SCLC drug talapoarib has its classical target PARP1, but through the chemical proteomics, it was found that unlike other PARP inhibitors, talazoparib might has another special target PARP16. The silencing of PARP16 could significantly inhibit cell survival, especially with the inhibition of PARP1. This enriched our knowledge about the possible mechanism behind the activity of talasoparib and provided a potential new therapeutic target PARP16 (64). A great number of possible therapeutic targets are gradually identified by utilizing proteomics. Coles et al. identified a total of 20 candidate kinases that were more active in SCLC cells than in normal lung or NSCLC cells. Among them, PKA was active to promote propagation of tumor cells in most SCLC cases, and the broad proteomic analysis figured out corresponding signaling networks in SCLC (65).
The management and monitoring of patients can be improved with certain proteomics methods. The preliminary studies showed that matrix-assisted laser desorption/ionization proteomics analysis could stratify SCLC patients and distinguish patients with disease control from those with progressive disease. Therefore, patients who could most benefit from EGFR tyrosine kinase inhibitor (TKI) will be identified (66). Dose-related efficacy of clinical drugs can be evaluated when methylation and acetylation levels of histones in cancer cells after chemotherapy were quantitatively determined using proteomics. For NSCLC, proteomics greatly advanced the development of its treatments. In terms of NSCLC radiotherapy, a study showed that two proteins, CRP and LRG1, which shown great changes in expression during radiotherapy, can be used to stratify patients early in radiotherapy, thereby providing more specific treatment for patients at different stages (67).
The application of proteomics can further explore the specific mechanisms of some drugs. Tivantiniba inhibits the metastasis potentials and deterioration of cancer cells by inhibiting the receptor tyrosine kinase c-MET, but unlike other inhibitors, it inhibits the activity of most NSCLC cell lines, indicating that its activity in NSCLC is not produced only by inhibiting c-MET. Remsing et al. applied an unbiased, mass-spectrometry-based, chemical proteomics approach, and they discovered two new targets of tivantiniba, GSK3 α and β, whose influences in NSCLC didn’t seem to overlap. Inhibiting them at the same time induced apoptosis more effectively in consequent experiments (68). AZD1775 has also shown monotherapy activity against NSCLC, although the underlying mechanism is unclear. An unbiased mass spectrometry-based chemical proteomics approach validated a new target, polo-like kinase 1, which might contribute to the anti-cancer activity of AZD1775 as a monotherapy when targeted with WEE1 simultaneously. Attention should be paid to its limitations as a highly selective WEE1 probe molecule when developing clinical anticancer application of AZD1775 (69).
Periplocin inhibits the growth of lung cancer cells both in vivo and in vitro, to explain its possible anti-cancer mechanism. Lu et al. found a total of 29 down-regulating proteins and 10 up-regulating proteins in periplocin-treated A549 cells compared to control groups, and the most important related function of these 39 proteins were transcription and proteolysis, which provided new insights for the use of periplocin on the treatment of lung cancer (70). Upon the knock-down of KMT9α (component of histone lysine methyl transferase KMT9) in A549 cells, RNA sequencing and mass spectrometry analysis revealed 460 target genes that were differentially expressed in both mRNA and protein levels, which were mainly enriched in the cell death, regulation of proliferation, as well as regulation of cell cycle pathways, and thus inhibited the proliferation of lung cancer cells and induced non-apoptotic cell death (71). Inhibitors targeting KMT9 might become a new kind of clinical agents. Abraxane (Abr) is an albumin-bound nanoparticle drug that was found to be more effective than pacificaxel (PTX) when used to treat NSCLC. In an experiment related to proteomics, the expression of only one protein, GNA1 was significantly changed in Abr and PTX-treated A549 cells. The decrease of this protein may inhibit growth and impair adhesion function of cancer cells (72). Through the mass spectrometry, Colzani et al. identified six new possible candidate kinase targets for anti-cancer multi-kinase inhibitor E-3810 on human NSCLC cells. Among them, the phosphorylation and activity of DDR2 was experimentally proved to be inhibited by micromolal dose of E-3810 in lung cancer cells overexpressing DDR2. Moreover, E-3810 in HCC-366 cells containing DDR2 mutations could also inhibit the proliferation of cancer cells. This helps us gain a deeper understanding of the mechanism behind the activity of E-3810 (73). Some molecules that are difficult to be exploited as direct drug targets may be proved to have significant influences on druggable molecules using proteomics. Nuclear receptor NR0B1 was identified as a potential druggable molecule for lung cancer dependent on the transcription factor NRF2 (74).
Further exploration of drug efficacy can be another application of proteomics. Huang et al. found that benzethonium chloride (BZN), an anti-infective drug might have some anti-cancer activities clinically because it led to the increase of 60 proteins and the decrease of 179 proteins in A549 cells, many of which are involved in cell cycle regulation (75). In a set of proteomics data, it was observed that RhoGDIα was significantly down regulated in A549 cells treated with 7,8-diacetoxy-4-methylcoumarin (DAMTC), and RhoGDIα regulated RhoA, Rac1 and Cdc42, thus affecting the formation of the cytoskeleton, which is closely related to the morphology, movement, adhesion and other functions of the cells. Therefore, DAMTC may block the migration and angiogenesis of cancer cells, with potential anti-cancer effects (76). OSU03013 was first found in proteomic studies to cause dephosphorylation of GSK3β in A549, CL1-1, H1435 cells, demonstrating the possibility of OSU03013 treating lung cancer (77). Proteomics also provides new ideas in the treatment of metastatic lung cancer. Integrated metabolomics and proteomics demonstrated that the activation of the Wnt/NR2F2/GPX4 axis in lung cancer patients with brain metastasis. Compared with primary lung cancer, the consumption of glutathione was high and two proteins (GPX4 and GSTM1) were up-regulated, which inhibited ferroptosis, and induced chemotherapy resistance and led to poor prognosis consequently. Experiments indicated GPX4 inhibitors could greatly improve the anti-cancer effect of platinum drugs on lung cancer patients with brain metastasis, which needs to be further verified (78). In cancer metastasis and development, cell-generated small extracellular vesicles (sEVs) are of great significance, there seem to have great relations, but with unclear mechanisms. The quantitative proteomics was performed on sEVs produced by highly metastatic lung cancer cells, and sEVs-HGF was recognized as a possible metastatic-related protein. Further studies showed that there existed a synergistic effect between sEVs-HGF and its transmembrane receptor c-Met, suggesting that HGF/c-Met pathway may be a potential therapeutic target for inhibiting lung cancer metastasis (79).
The applications of proteomics can provide more possibilities for drug combination. The phenotypic drug screening proved that midostaurin has strong activity independent of PKC in NSCLC cells. Ctortecka et al. discovered numerous targets and corresponding pathways for midostaurin, such as TBK1, PDPK1, and AURKA, as well as PLK1. In combination with PLK1 inhibitors like BI2536, midostaurin seemed to produce a strong synergistic effect. The study provided a comprehensive insight into midostaurin and enhance the rational design of the combination approach to midostaurin (80). Dasatinib is another clinical drug for NSCLC. To explore the mechanism underlying the anti-cancer activity of dasatinib, chemical proteomics and immunoaffinity purification were combined, and 40 possible kinase targets were finally identified, including SFK members, non-receptor tyrosine kinases, and receptor tyrosine kinases, which could contain functional targets of dasatinib and provide possible combination therapy options (81).
The efficacy of treatment needs to be screened and predicted for better treatment and management of patients. For chemotherapy, in a study, serum MALDI was used to successfully predicted prognosis of NSCLC patients after the treatment of erlotinib (82). Patients accepting radiotherapy can sometimes develop lung toxicity, with multiplex quantitative proteomics approaches to examine platelet-poor plasma obtained from 57 eligible NSCLC patients after radiotherapy, C4BPA and VTN were significantly identified to be up-regulated in patients with grade 2 radiation-induced lung toxicity, while immunoglobulin kappa chain V-III region Ti and region HAH were opposite. The further analysis was conducted to develop three models with better accuracy, including VTN alone, C4BPA + VTN, and C4BPA alone to help predict the occurrence of later grade≥2 radiation-induced lung toxicity (RILT2) (83). In terms of surgical efficacy prediction, proteomics also has certain application value, early recurrence of LSCC after surgery is an important factor for the poor prognosis. With proteomics, Wu et al. figured out that DDX56, one of the members of DEAD-Box Helicase (DDX) family, increased significantly in a group of primary tumor tissues of 20 patients with early recurrent LSCC. Through further pathway enrichment analysis and cytology experimental studies, it was found that DDX56 might influence the incidence of recurrence and survival by miRNA-mediated post-transcriptional regulation of the Wnt signaling pathway (84). A panel of genes was selected by Sharpnack et al., including SUMO1, PCBD1, PSMC5, ARCN1, PPA2, and SRI. They combined corresponding RNAs and proteins to form integral biomarkers, which can better predict the recurrence of LUAD after surgery (85).
Some datasets constructed by proteomics are used for evaluation of treatments. Chen et al. collected tumor tissues and matched normal adjacent tissues (NATs) from 103 untreated lung cancer patients, and built a comprehensive proteomics landscape of east Asian non-smoking LUAD populations to provide strategies and candidate biomarkers for patient stratification, intervention and treatment management (86). Another research attempted to combine different kinds of techniques to complete multiomics analysis and build a dataset on the basis of 110 LUAD tissues and 101 corresponding normal tissues, which may have a promoting effect on the treatment of LUAD (87). Furthermore, an NSCLC subtype classification strategy based on DIA-MS was validated in a cohort of 208 NSCLC patients for better management of late-stage NSCLC patients management (88).
Role in the mechanisms of resistance
In the clinical treatment of lung cancer, drug resistance is one of the issues that need to be solve urgently, and proteomics plays an important role in exploring the mechanisms of drug resistance. Some pathways have been found to be associated with radiotherapy and chemotherapy resistance to lung cancer. For example, the activation of the PI3K/AKT pathway may be associated with SCLC chemoradiotherapy resistance label-free through mass spectrometry-based proteomics combined with whole-exome sequencing (89).
Cisplatin is a classic drug for lung cancer, and is also one of the drugs prone to drug resistance. Böttger et al. constructed a kind of RPF mouse model by overexpressing the carcinogen Nfifib based on the classical SCLC RP mouse model, and they treated the RPF mice with vector and cisplatin. Comparing lung tissue samples of the vector-treated mice (V-RPF) and cisplatin-treated RPF-Rep mice, a total of 274 differentially expressed proteins were identified, of which 101 were more abundant in RPF-Rep samples, CDH1 in particular, which induced cisplatin resistance by mediating cell-to-cell contact to upregulate the PI3K-AKT pathway. Moreover, 173 differentially expressed proteins were reduced in RPF-Rep samples and a wide set of neuronal differentiation and migration-associated genes were significantly reduced, indicating that cisplatin therapy may induce the transfer to less pronounced neuronal phenotype (90). At the cellular level, 157 upregulated proteins and 140 down-regulating proteins were identified in the cisplatin-resistant A549 cells through quantitative proteomic analysis of cell membrane proteins. Further GO and KEGG analysis showed that proteins up-regulated were mostly associated with enhanced cell adhesion function, thereby enhancing the resistance to cisplatin while those down-regulated tended to be related to signal transduction and cell migration. In addition, LRRC8A, which greatly influences cisplatin uptake, was also downregulated, which reduced cisplatin uptake considerably and was also involved in the generation of cisplatin resistance (91). And in another study, the SILAC proteomics identified high expression of GRP78 and other proteins associated with anti-apoptotic and/or autophagy promotion, which might also contribute to cisplatin resistance (92). Milone et al. performed proteomic approaches to compare the constructed cisplatin-resistant A549 cell line and its parents, and found 13 up-regulated and 2 down-regulated proteins. The interaction networks showed that these proteins may contribute to the development of drug resistance by influencing protein folding and endoplasmic reticulum stress, and consequent increased NSCLC cell aggressiveness (93). Some molecules related to cisplatin resistance mechanism can also be used as a predictor of prognosis of cisplatin treatment. After a 2-DE analysis to compare A549 and cisplatin-resistant A549/DDP cells quantitatively, 9 up-regulated and 3 down-regulated proteins were identified, and DJ-1 was selected for further verification with the western blotting. Then 67 clinical cases were grouped according to the expression of DJ-1. Interestingly, the group with high DJ-1 expression was found to have a significant decrease in overall survival, while the silencing of DJ-1 in A549/DDP cells could partially rescue the responsiveness to cisplatin, and hence DJ-1 might contribute to cisplatin resistance and could also be a potential predictor of prognosis of cisplatin therapy (94).
EGFR inhibitors are often used to treat NSCLC, but some patients inevitably develop resistance to them, and proteomics found that oncogenic transcription factor BCL6 inhibited the transcription of multiple target genes, thereby resulting in reduced apoptosis, which suggested that BCL6 may be an important target for EGFR inhibitor resistance. The consequent experiments demonstrated that targeting both EGFR and BCL6 at the same time would have a potent synergistic effect on killing lung cancer cells, which also provided new combination therapy regimens (95). Osimertinib is a third-generation EGFR TKI for EGFR T790M mutation. However, resistance has still developed. By comparing the proteome and phosphoproteome of mutated LUAD cells sensitive and resistant to osimertinib, the overall proteomic changes of three generations of EGFR TKI resistance were identified, in which mass spectrometry showed that epithelial-mesenchymal transition (EMT) may be associated with osimertinib resistance. In addition, significant changes at important phosphorylation sites on kinases in drug-resistant cells might be part of the mechanisms underlying the generation of the resistance (96). In cell lines resistant to EGFR TKIs, Terp et al. applied spectrometry-based proteomics, and they found that the expression of FGFR1 was significantly increased, and the Akt pathway was abnormally activated. The combination of EGFR and Akt inhibitors might be a possible clinical treatment strategy (97). A group of data from quantitative proteomics, which examined pleural effusions in advanced LUAD patients with EGFR TKI resistance and control group, selected 15 preliminary candidate proteins for further study. The content of CDH3 in the pleural effusion of resistant patients was significantly increased, and influenced the progression-free survival and overall survival. Therefore, CDH3 may be associated with EGFR TKI resistance (98).
Abraxane is nanoparticle form of PTX, after comparing the protein expression profiles of A549 cell lines sensitive and resistant to abraxane by combining quantitative proteomics and GO analysis, these results demonstrated that most of the up-regulated proteins in resistant cells were predominantly enriched in lipid biosynthesis and amino acids metabolism-related pathways, while down-regulated proteins were primarily associated with cytoskeleton and cell adhesion. Some of these proteins were not discovered in previous studies about PTX resistance and this study provided new ideas for following researches on the resistance of nanoparticle form drugs (99). Tufo et al. performed an unbiased approach to detect endoplasmic reticulum proteins in NSCLC A549 cell lines resistant to long-term cis-diaminedichloroplatine(II) (CDDP), and they found significant up-regulation of PDIA4 and PDIA6, which possibly mediated CDDP resistance (100). Microtubule interacting agents (MIAs) are commonly used in the clinic for oncology treatment, but some lung cancer patients have gradually developed resistance to MIAs. Albrethsen et al. applied proteomic analysis to A549 cell lines, a taxol resistant cell line, and an epothilone B resistant cell line. Galectin-1 was found to be up-regulated considerably, indicating that galectin-1 might contribute to the development of resistance to microtubule stabilizer (101).
Conclusions
Proteomics is a necessary piece of the puzzle of multi-omics, which has played an important role in lung cancer-related study, with great value and application prospects. Proteomics techniques can be combined with a variety of other technologies, when combined with molecular technologies, further exploration of mechanisms will be attained, and protein landscape or related dataset can be built with the combination of computer technologies, thus synthesizing different information to form a comprehensive network. However, it should be noticed that there are still some problems in the application of proteomics. For example, how to further improve the sensitivity and specificity of biomarkers of diagnosis, and how to determine the optimal model in prognosis prediction. The solution to these issues depends not only on the development and innovation of proteomics techniques, but also on combination of technologies and experiments. More studies are needed to further advance the applications of proteomics in lung cancer.
This article reviewed application of proteomics in lung cancer in the last twenty years, and paid attention to relatively comprehensive aspects including tumorigenesis, diagnosis, prognosis, treatment and resistance of lung cancer. And we discussed this topic in different lung cancer typing (NSCLC and SCLC), which was more specific to some extent. We concluded an amount of potential proteomic biomarkers and some related pathways, which might promote further clinical validation and provide insights and direction for future research.
Author contributions
BL and ZZ had the idea for the article. ZX, YC and XZ performed the literature search and data analysis. JW drafted and critically revised the work. All authors contributed to the article and approved the submitted version.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
References
1. Oliver AL. Lung cancer: Epidemiology and screening. Surg Clin North Am (2022) 102(3):335–44. doi: 10.1016/j.suc.2021.12.001
2. Thai AA, Solomon BJ, Sequist LV, Gainor JF, Heist RS. Lung cancer. Lancet (2021) 398(10299):535–54. doi: 10.1016/s0140-6736(21)00312-3
3. Huang F, Zhao Y. Global control of tuberculosis: Current status and future prospects. Zoonoses (2022).
4. Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in nsclc. Nat Rev Cancer (2017) 17(11):637–58. doi: 10.1038/nrc.2017.84
5. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc (2019) 94(8):1623–40. doi: 10.1016/j.mayocp.2019.01.013
6. Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc (2019) 94(8):1599–622. doi: 10.1016/j.mayocp.2019.01.034
7. Sung HJ, Ahn JM, Yoon YH, Na SS, Choi YJ, Kim YI, et al. Quiescin sulfhydryl oxidase 1 (Qsox1) secreted by lung cancer cells promotes cancer metastasis. Int J Mol Sci (2018) 19(10):3213. doi: 10.3390/ijms19103213
8. Wu J, Chen Z-P, Shang A-Q, Wang W-W, Chen Z-N, Tao Y-J, et al. Systemic bioinformatics analysis of recurrent aphthous stomatitis gene expression profiles. Oncotarget (2017) 8(67):111064. doi: 10.18632/oncotarget.22347
9. Wu J, Lu WY, Cui LL. Clinical significance of Stat3 and mapk phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. Mol Med Rep (2015) 12(6):8129–34. doi: 10.3892/mmr.2015.4460
10. Wu J, Cui LL, Yuan J, Wang Y, Song S. Clinical significance of the phosphorylation of mapk and protein expression of cyclin D1 in human osteosarcoma tissues. Mol Med Rep (2017) 15(4):2303–7. doi: 10.3892/mmr.2017.6224
11. Menyhart O, Gyorffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J (2021) 19:949–60. doi: 10.1016/j.csbj.2021.01.009
12. Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature (2019) 567(7747):257–61. doi: 10.1038/s41586-019-0987-8
13. de Sousa VML, Carvalho L. Heterogeneity in lung cancer. Pathobiology (2018) 85(1-2):96–107. doi: 10.1159/000487440
15. Osmani L, Askin F, Gabrielson E, Li QK. Current who guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (Nsclc): Moving from targeted therapy to immunotherapy. Semin Cancer Biol (2018) 52(Pt 1):103–9. doi: 10.1016/j.semcancer.2017.11.019
16. Aslam B, Basit M, Nisar MA, Khurshid M, Rasool MH. Proteomics: Technologies and their applications. J Chromatogr Sci (2017) 55(2):182–96. doi: 10.1093/chromsci/bmw167
17. Cheung CHY, Juan HF. Quantitative proteomics in lung cancer. J BioMed Sci (2017) 24(1):37. doi: 10.1186/s12929-017-0343-y
18. Cifani P, Kentsis A. Towards comprehensive and quantitative proteomics for diagnosis and therapy of human disease. Proteomics (2017) 17(1-2):10. doi: 10.1002/pmic.201600079
19. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: A review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med (2008) 23 Suppl 1(Suppl 1):78–84. doi: 10.1007/s11606-007-0411-1
20. Li X, Wang W, Chen J. Recent progress in mass spectrometry proteomics for biomedical research. Sci China Life Sci (2017) 60(10):1093–113. doi: 10.1007/s11427-017-9175-2
21. Hoehn GT, Suffredini AF. Proteomics. Crit Care Med (2005) 33(12 Suppl):S444–8. doi: 10.1097/01.ccm.0000187001.44171.5e
22. Gasparri R, Sedda G, Noberini R, Bonaldi T, Spaggiari L. Clinical application of mass spectrometry-based proteomics in lung cancer early diagnosis. Proteomics Clin Appl (2020) 14(5):e1900138. doi: 10.1002/prca.201900138
23. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, et al. Stable isotope labeling by amino acids in cell culture, silac, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics (2002) 1(5):376–86. doi: 10.1074/mcp.m200025-mcp200
24. Wiese S, Reidegeld KA, Meyer HE, Warscheid B. Protein labeling by itraq: A new tool for quantitative mass spectrometry in proteome research. Proteomics (2007) 7(3):340–50. doi: 10.1002/pmic.200600422
25. Thompson A, Schäfer J, Kuhn K, Kienle S, Schwarz J, Schmidt G, et al. Tandem mass tags: A novel quantification strategy for comparative analysis of complex protein mixtures by Ms/Ms. Anal Chem (2003) 75(8):1895–904. doi: 10.1021/ac0262560
26. Fernández-Costa C, Martínez-Bartolomé S, McClatchy DB, Saviola AJ, Yu NK, Yates JR 3rd. Impact of the identification strategy on the reproducibility of the dda and dia results. J Proteome Res (2020) 19(8):3153–61. doi: 10.1021/acs.jproteome.0c00153
27. McCarroll JA, Gan PP, Erlich RB, Liu M, Dwarte T, Sagnella SS, et al. Tubb3/Βiii-tubulin acts through the Pten/Akt signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer. Cancer Res (2015) 75(2):415–25. doi: 10.1158/0008-5472.Can-14-2740
28. Chen X, Yu C, Gao J, Zhu H, Cui B, Zhang T, et al. A novel Usp9x substrate ttk contributes to tumorigenesis in non-Small-Cell lung cancer. Theranostics (2018) 8(9):2348–60. doi: 10.7150/thno.22901
29. Rahman SMJ, Ji X, Zimmerman LJ, Li M, Harris BK, Hoeksema MD, et al. The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer. JCI Insight (2016) 1(19):e88814. doi: 10.1172/jci.insight.88814
30. Chang YH, Lee SH, Liao IC, Huang SH, Cheng HC, Liao PC. Secretomic analysis identifies alpha-1 antitrypsin (A1at) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics (2012) 11(11):1320–39. doi: 10.1074/mcp.M112.017384
31. Min H, Han D, Kim Y, Cho JY, Jin J, Kim Y. Label-free quantitative proteomics and n-terminal analysis of human metastatic lung cancer cells. Mol Cells (2014) 37(6):457–66. doi: 10.14348/molcells.2014.0035
32. Pal J, Becker AC, Dhamija S, Seiler J, Abdelkarim M, Sharma Y, et al. Systematic analysis of migration factors by migexpress identifies essential cell migration control genes in non-small cell lung cancer. Mol Oncol (2021) 15(7):1797–817. doi: 10.1002/1878-0261.12973
33. Thu KL, Silvester J, Elliott MJ, Ba-Alawi W, Duncan MH, Elia AC, et al. Disruption of the anaphase-promoting complex confers resistance to ttk inhibitors in triple-negative breast cancer. Proc Natl Acad Sci U.S.A. (2018) 115(7):E1570–E7. doi: 10.1073/pnas.1719577115
34. Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell (2021) 184(16):4348–71.e40. doi: 10.1016/j.cell.2021.07.016
35. Sun Z, Chen X, Wang G, Li L, Fu G, Kuruc M, et al. Identification of functional metabolic biomarkers from lung cancer patient serum using pep technology. biomark Res (2016) 4:11. doi: 10.1186/s40364-016-0065-4
36. Sun Y, Liu S, Qiao Z, Shang Z, Xia Z, Niu X, et al. Systematic comparison of exosomal proteomes from human saliva and serum for the detection of lung cancer. Anal Chim Acta (2017) 982:84–95. doi: 10.1016/j.aca.2017.06.005
37. Wang N, Song X, Liu L, Niu L, Wang X, Song X, et al. Circulating exosomes contain protein biomarkers of metastatic non-Small-Cell lung cancer. Cancer Sci (2018) 109(5):1701–9. doi: 10.1111/cas.13581
38. Boccellino M, Pinto F, Ieluzzi V, Giovane A, Quagliuolo L, Fariello C, et al. Proteomics analysis of human serum of patients with non-Small-Cell lung cancer reveals proteins as diagnostic biomarker candidates. J Cell Physiol (2019) 234(12):23798–806. doi: 10.1002/jcp.28948
39. He P, Naka T, Serada S, Fujimoto M, Tanaka T, Hashimoto S, et al. Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci (2007) 98(8):1234–40. doi: 10.1111/j.1349-7006.2007.00509.x
40. Patz EF Jr., Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol (2007) 25(35):5578–83. doi: 10.1200/jco.2007.13.5392
41. Li B, Chang J, Chu Y, Kang H, Yang J, Jiang J, et al. Membrane proteomic analysis comparing squamous cell lung cancer tissue and tumour-adjacent normal tissue. Cancer Lett (2012) 319(1):118–24. doi: 10.1016/j.canlet.2011.12.037
42. Kim SW, Cheon K, Kim CH, Yoon JH, Hawke DH, Kobayashi R, et al. Proteomics-based identification of proteins secreted in apical surface fluid of squamous metaplastic human tracheobronchial epithelial cells cultured by three-dimensional organotypic air-liquid interface method. Cancer Res (2007) 67(14):6565–73. doi: 10.1158/0008-5472.Can-06-2783
43. Ahn JM, Sung HJ, Yoon YH, Kim BG, Yang WS, Lee C, et al. Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol Cell Proteomics (2014) 13(1):30–48. doi: 10.1074/mcp.M113.028621
44. Zhou X, Xue L, Hao L, Liu S, Zhou F, Xiong H, et al. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma. BioMed Pharmacother (2013) 67(7):621–7. doi: 10.1016/j.biopha.2013.06.005
45. Guergova-Kuras M, Kurucz I, Hempel W, Tardieu N, Kadas J, Malderez-Bloes C, et al. Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol Cell Proteomics (2011) 10(12).
46. Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, et al. Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol Cell Proteomics (2016) 15(7):2396–410. doi: 10.1074/mcp.M115.057026
47. Li P, Zhang Y, Xu Y, Cao H, Li L. Characteristics of Cd8+ and Cd4+ tissue-resident memory lymphocytes in the gastrointestinal tract. Advanced Gut Microbiome Res (2022) 2022.
48. Bouamrani A, Ternier J, Ratel D, Benabid AL, Issartel JP, Brambilla E, et al. Direct-tissue seldi-tof mass spectrometry analysis: A new application for clinical proteomics. Clin Chem (2006) 52(11):2103–6. doi: 10.1373/clinchem.2006.070979
49. Nishimura T, Kawamura T, Sugihara Y, Bando Y, Sakamoto S, Nomura M, et al. Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing biobank repositories. Clin Transl Med (2014) 3(1):61. doi: 10.1186/s40169-014-0038-x
50. Lopez-Sanchez LM, Jurado-Gamez B, Feu-Collado N, Valverde A, Canas A, Fernandez-Rueda JL, et al. Exhaled breath condensate biomarkers for the early diagnosis of lung cancer using proteomics. Am J Physiol Lung Cell Mol Physiol (2017) 313(4):L664–L76. doi: 10.1152/ajplung.00119.2017
51. Jiang X, Chen X, Chen Z, Yu J, Lou H, Wu J. High-throughput salivary metabolite profiling on an ultralow noise tip-enhanced laser desorption ionization mass spectrometry platform for noninvasive diagnosis of early lung cancer. J Proteome Res (2021) 20(9):4346–56. doi: 10.1021/acs.jproteome.1c00310
52. Pan J, Song G, Chen D, Li Y, Liu S, Hu S, et al. Identification of serological biomarkers for early diagnosis of lung cancer using a protein array-based approach. Mol Cell Proteomics (2017) 16(12):2069–78. doi: 10.1074/mcp.RA117.000212
53. Jin Y, Yang Y, Su Y, Ye X, Liu W, Yang Q, et al. Identification a novel clinical biomarker in early diagnosis of human non-small cell lung cancer. Glycoconj J (2019) 36(1):57–68. doi: 10.1007/s10719-018-09853-z
54. Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung cancer. Ann Glob Health (2019) 85(1):8. doi: 10.5334/aogh.2419
55. Wheatley-Price P, Blackhall F, Lee SM, Ma C, Ashcroft L, Jitlal M, et al. The influence of sex and histology on outcomes in non-Small-Cell lung cancer: A pooled analysis of five randomized trials. Ann Oncol (2010) 21(10):2023–8. doi: 10.1093/annonc/mdq067
56. Izbicka E, Streeper RT, Michalek JE, Louden CL, Diaz A 3rd, Campos DR.Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics (2012) 9(1):27.
57. Wang S, Cowley LA, Liu XS. Sex differences in cancer immunotherapy efficacy, biomarkers, and therapeutic strategy. Molecules (2019) 24(18):3214. doi: 10.3390/molecules24183214
58. Ramsey JM, Cooper JD, Penninx BW, Bahn S. Variation in serum biomarkers with sex and female hormonal status: Implications for clinical tests. Sci Rep (2016) 6:26947. doi: 10.1038/srep26947
59. Dingemans AM, Mellema WW, Groen HJ, van Wijk A, Burgers SA, Kunst PW, et al. A phase ii study of sorafenib in patients with platinum-pretreated, advanced (Stage iiib or iv) non-small cell lung cancer with a kras mutation. Clin Cancer Res (2013) 19(3):743–51. doi: 10.1158/1078-0432.Ccr-12-1779
60. Xu JY, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell (2020) 182(1):245–61.e17. doi: 10.1016/j.cell.2020.05.043
61. Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, et al. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Sci Adv (2020) 6(11):eaaz6162. doi: 10.1126/sciadv.aaz6162
62. Liu Z, Xu S, Li L, Zhong X, Chen C, Fan Y, et al. Comparative mitochondrial proteomic analysis of human Large cell lung cancer cell lines with different metastasis potential. Thorac Cancer (2019) 10(5):1111–28. doi: 10.1111/1759-7714.13052
63. Yin YP, Shi WH, Deng K, Liu XL, Li H, Lv XT, et al. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer. Acta Pharmacol Sin (2021) 42(8):1298–310. doi: 10.1038/s41401-020-00544-w
64. Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, et al. The non-canonical target Parp16 contributes to polypharmacology of the parp inhibitor talazoparib and its synergy with Wee1 inhibitors. Cell Chem Biol (2022) 29(2):202–14.e7. doi: 10.1016/j.chembiol.2021.07.008
65. Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, et al. Unbiased proteomic profiling uncovers a targetable Gnas/Pka/Pp2a axis in small cell lung cancer stem cells. Cancer Cell (2020) 38(1):129–43.e7. doi: 10.1016/j.ccell.2020.05.003
66. O'Byrne KJ, Danson S, Dunlop D, Botwood N, Taguchi F, Carbone D, et al. Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. J Clin Oncol (2007) 25(22):3266–73. doi: 10.1200/jco.2006.09.2791
67. Walker MJ, Zhou C, Backen A, Pernemalm M, Williamson AJ, Priest LJ, et al. Discovery and validation of predictive biomarkers of survival for non-small cell lung cancer patients undergoing radical radiotherapy: Two proteins with predictive value. EBioMedicine (2015) 2(8):841–50. doi: 10.1016/j.ebiom.2015.06.013
68. Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, et al. Gsk3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol (2014) 9(2):353–8. doi: 10.1021/cb400660a
69. Wright G, Golubeva V, Remsing Rix LL, Berndt N, Luo Y, Ward GA, et al. Dual targeting of Wee1 and Plk1 by Azd1775 elicits single agent cellular anticancer activity. ACS Chem Biol (2017) 12(7):1883–92. doi: 10.1021/acschembio.7b00147
70. Lu Z, Song Q, Yang J, Zhao X, Zhang X, Yang P, et al. Comparative proteomic analysis of anti-cancer mechanism by periplocin treatment in lung cancer cells. Cell Physiol Biochem (2014) 33(3):859–68. doi: 10.1159/000358658
71. Baumert HM, Metzger E, Fahrner M, George J, Thomas RK, Schilling O, et al. Depletion of histone methyltransferase Kmt9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death. Cancer Cell Int (2020) 20:52. doi: 10.1186/s12935-020-1141-2
72. Zhao M, Li H, Ma Y, Gong H, Yang S, Fang Q, et al. Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate n-acetyltransferase 1 (Gnpnat1/Gna1). Int J Nanomedicine (2017) 12:1685–97. doi: 10.2147/ijn.S129976
73. Colzani M, Noberini R, Romanenghi M, Colella G, Pasi M, Fancelli D, et al. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor e-3810. Mol Cell Proteomics (2014) 13(6):1495–509. doi: 10.1074/mcp.M113.034173
74. Bar-Peled L, Kemper EK, Suciu RM, Vinogradova EV, Backus KM, Horning BD, et al. Chemical proteomics identifies druggable vulnerabilities in a genetically defined cancer. Cell (2017) 171(3):696–709.e23. doi: 10.1016/j.cell.2017.08.051
75. Huang XH, Wang Y, Hong P, Yang J, Zheng CC, Yin XF, et al. Benzethonium chloride suppresses lung cancer tumorigenesis through inducing P38-mediated cyclin D1 degradation. Am J Cancer Res (2019) 9(11):2397–412.
76. Goel A, Chhabra R, Ahmad S, Prasad AK, Parmar VS, Ghosh B, et al. Damtc regulates cytoskeletal reorganization and cell motility in human lung adenocarcinoma cell line: An integrated proteomics and transcriptomics approach. Cell Death Dis (2012) 3(10):e402. doi: 10.1038/cddis.2012.141
77. Tan YH, Lee KH, Lin T, Sun YC, Hsieh-Li HM, Juan HF, et al. Cytotoxicity and proteomics analyses of Osu03013 in lung cancer. Clin Cancer Res (2008) 14(6):1823–30. doi: 10.1158/1078-0432.Ccr-07-1806
78. Liu W, Zhou Y, Duan W, Song J, Wei S, Xia S, et al. Glutathione peroxidase 4-dependent glutathione high-consumption drives acquired platinum chemoresistance in lung cancer-derived brain metastasis. Clin Transl Med (2021) 11(9):e517. doi: 10.1002/ctm2.517
79. Qiao Z, Zhang Y, Ge M, Liu S, Jiang X, Shang Z, et al. Cancer cell derived small extracellular vesicles contribute to recipient cell metastasis through promoting Hgf/C-met pathway. Mol Cell Proteomics (2019) 18(8):1619–29. doi: 10.1074/mcp.RA119.001502
80. Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, et al. Functional proteomics and deep network interrogation reveal a complex mechanism of action of midostaurin in lung cancer cells. Mol Cell Proteomics (2018) 17(12):2434–47. doi: 10.1074/mcp.RA118.000713
81. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol (2010) 6(4):291–9. doi: 10.1038/nchembio.332
82. Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, et al. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern cooperative oncology group 3503. J Thorac Oncol (2010) 5(2):169–78. doi: 10.1097/JTO.0b013e3181c8cbd9
83. Cai XW, Shedden KA, Yuan SH, Davis MA, Xu LY, Xie CY, et al. Baseline plasma proteomic analysis to identify biomarkers that predict radiation-induced lung toxicity in patients receiving radiation for non-small cell lung cancer. J Thorac Oncol (2011) 6(6):1073–8. doi: 10.1097/JTO.0b013e3182152ba6
84. Wu Q, Luo X, Terp MG, Li Q, Li Y, Shen L, et al. Ddx56 modulates post-transcriptional wnt signaling through mirnas and is associated with early recurrence in squamous cell lung carcinoma. Mol Cancer (2021) 20(1):108. doi: 10.1186/s12943-021-01403-w
85. Sharpnack MF, Ranbaduge N, Srivastava A, Cerciello F, Codreanu SG, Liebler DC, et al. Proteogenomic analysis of surgically resected lung adenocarcinoma. J Thorac Oncol (2018) 13(10):1519–29. doi: 10.1016/j.jtho.2018.06.025
86. Chen YJ, Roumeliotis TI, Chang YH, Chen CT, Han CL, Lin MH, et al. Proteogenomics of non-smoking lung cancer in East Asia delineates molecular signatures of pathogenesis and progression. Cell (2020) 182(1):226–44.e17. doi: 10.1016/j.cell.2020.06.012
87. Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell (2020) 182(1):200–25.e35. doi: 10.1016/j.cell.2020.06.013
88. Lehtio J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, et al. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms. Nat Cancer (2021) 2(11):1224–42. doi: 10.1038/s43018-021-00259-9
89. Jin Y, Chen Y, Tang H, Hu X, Hubert SM, Li Q, et al. Activation of Pi3k/Akt pathway is a potential mechanism of treatment resistance in small cell lung cancer. Clin Cancer Res (2022) 28(3):526–39. doi: 10.1158/1078-0432.Ccr-21-1943
90. Böttger F, Semenova EA, Song JY, Ferone G, van der Vliet J, Cozijnsen M, et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer. Cell Rep (2019) 27(11):3345–58.e4. doi: 10.1016/j.celrep.2019.05.057
91. Zeng W, Zheng S, Mao Y, Wang S, Zhong Y, Cao W, et al. Elevated n-glycosylation contributes to the cisplatin resistance of non-small cell lung cancer cells revealed by membrane proteomic and glycoproteomic analysis. Front Pharmacol (2021) 12:805499. doi: 10.3389/fphar.2021.805499
92. Wang Z, Liu G, Jiang J. Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture. Int J Oncol (2019) 54(3):1071–85. doi: 10.3892/ijo.2019.4690
93. Milone MR, Lombardi R, Roca MS, Bruzzese F, Addi L, Pucci B, et al. Novel pathways involved in cisplatin resistance identified by a proteomics approach in non-Small-Cell lung cancer cells. J Cell Physiol (2019) 234(6):9077–92. doi: 10.1002/jcp.27585
94. Zeng HZ, Qu YQ, Zhang WJ, Xiu B, Deng AM, Liang AB. Proteomic analysis identified dj-1 as a cisplatin resistant marker in non-small cell lung cancer. Int J Mol Sci (2011) 12(6):3489–99. doi: 10.3390/ijms12063489
95. Zhou Tran Y, Minozada R, Cao X, Johansson HJ, Branca RM, Seashore-Ludlow B, et al. Immediate adaptation analysis implicates Bcl6 as an egfr-tki combination therapy target in nsclc. Mol Cell Proteomics (2020) 19(6):928–43. doi: 10.1074/mcp.RA120.002036
96. Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, et al. Alterations in the global proteome and phosphoproteome in third generation egfr tki resistance reveal drug targets to circumvent resistance. Cancer Res (2021) 81(11):3051–66. doi: 10.1158/0008-5472.Can-20-2435
97. Terp MG, Jacobsen K, Molina MA, Karachaliou N, Beck HC, Bertran-Alamillo J, et al. Combined fgfr and akt pathway inhibition abrogates growth of Fgfr1 overexpressing egfr-Tki-Resistant nsclc cells. NPJ Precis Oncol (2021) 5(1):65. doi: 10.1038/s41698-021-00208-w
98. Hsiao TF, Wang CL, Wu YC, Feng HP, Chiu YC, Lin HY, et al. Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of egfr tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res (2020) 26(13):3220–9. doi: 10.1158/1078-0432.Ccr-19-3972
99. Zhao M, Li H, Bu X, Lei C, Fang Q, Hu Z. Quantitative proteomic analysis of cellular resistance to the nanoparticle abraxane. ACS Nano (2015) 9(10):10099–112. doi: 10.1021/acsnano.5b03677
100. Tufo G, Jones AW, Wang Z, Hamelin J, Tajeddine N, Esposti DD, et al. The protein disulfide isomerases Pdia4 and Pdia6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ (2014) 21(5):685–95. doi: 10.1038/cdd.2013.193
Keywords: lung cancer, proteomics, tumorigenesis, diagnosis, treatment
Citation: Ling B, Zhang Z, Xiang Z, Cai Y, Zhang X and Wu J (2022) Advances in the application of proteomics in lung cancer. Front. Oncol. 12:993781. doi: 10.3389/fonc.2022.993781
Received: 16 July 2022; Accepted: 29 August 2022;
Published: 27 September 2022.
Edited by:
Luka Brcic, Medical University of Graz, AustriaReviewed by:
Tamara Tomin, Vienna University of Technology, AustriaParamjit S. Tappia, I.H. Asper Clinical Research Institute, Canada
Copyright © 2022 Ling, Zhang, Xiang, Cai, Zhang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jian Wu, wujianglinxing@163.com
†These authors have contributed equally to this work